الإحصائيات الأساسية
| CIK | 1865494 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IO Biotech, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| August 14, 2025 |
EX-99.1 Exhibit 99.1 IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights • Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet with FDA this fall to discuss |
|
| August 11, 2025 |
EX-99.2 Breaking Boundaries. Igniting Change. IO Biotech Conference Call Pivotal Phase 3 Trial Results 11August2025 Exhibit 99.2 DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amende |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2025 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 11, 2025 |
EX-99.1 Exhibit 99.1 IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed • Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression |
|
| July 24, 2025 |
As filed with the Securities and Exchange Commission on July 24, 2025 Table of Contents As filed with the Securities and Exchange Commission on July 24, 2025 Registration No. |
|
| July 24, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) IO Biotech, Inc. |
|
| June 27, 2025 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 27, 2025 |
Tranche B Warrant, dated as of June 24, 2025 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 19, 2025 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 20, 2025 |
Addendum, dated June 19, by and between the Company and the CEO EX-10.1 Exhibit 10.1 This addendum to the service agreement (“Service Agreement”) dated 21 August 2017 (the “Addendum”) is entered into between: IO Biotech ApS [***] (the “Company”) and Mai-Britt Zocca (the “CEO”) 1. Severance 1.1 Effective 19 June 2025, if the Company terminates the CEO’s employment without Cause or the CEO resigns for Good Reason (as such terms are defined below) and subject to |
|
| June 9, 2025 |
IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N CORRESP IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark June 9, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tim Buchmiller Re: IO Biotech, Inc. Registration Statement on Form S-3, as amended File No. 333-287554 Acceleration Request Requested Date: June 11, 2025 Requested Time: 4:00 |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2025 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 23, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) IO Biotech, Inc. |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 23, 2025 Registration No. |
|
| May 14, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2025 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| May 14, 2025 |
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights Exhibit 99.1 IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights • Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 • Data presented at recent congresses reinforces the potential of the company’s T-Win candidates to reshape t |
|
| April 30, 2025 |
Tranche A Warrant, dated as of April 24, 2025 Exhibit 4.1 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 7, 2025 |
As filed with the Securities and Exchange Commission on April 7, 2025 S-8 As filed with the Securities and Exchange Commission on April 7, 2025 Registration No. |
|
| April 7, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) IO BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share 4 |
|
| March 31, 2025 |
Policy on Recoupment of Incentive Compensation, dated September 20, 2023, of IO Biotech Inc. Exhibit 97.1 IO BIOTECH, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of IO Biotech, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a re |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41008 IO Biotech, Inc |
|
| March 31, 2025 |
Insider Trading Policy of IO Biotech, Inc., effective as of October 31, 2021 Exhibit 19.1 Insider Trading Policy As adopted by the Board of Directors, effective October 31, 2021 Introduction This policy determines acceptable transactions in the securities of IO Biotech, Inc. (the “Company” or “IO Biotech”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information th |
|
| March 31, 2025 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary describes the capital stock of IO Biotech, Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the investors’ rights agreement to which we and certain stockholders are parties (the “IRA”) and of the General Corporation Law |
|
| March 4, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2025 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 4, 2025 |
IO Biotech Reports 2024 Business Highlights Exhibit 99.1 IO Biotech Reports 2024 Business Highlights • Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS); the rat |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025100255.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT We, the undersigned, hereby express our agreement that the Schedule 13G (or any amendments thereto) relating to the common stock of IO Biotech, Inc. is filed on behalf of each of us. Dated: February 14, 2024 Samsara BioCapital, L.P. By: Samsara BioCapital GP, LLC its General Partner By: /s/ Srinivas Akkar |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 20, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 20, 2024 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT IO BIOTECH (IEU LS) (Serapis No: 2024-0179; FI No: 97869) THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 19, 2024, is entered into by and between IO BIOTECH, INC., a Delaware corporation (the “Company”), and the European Investment Bank, having its seat at 98-100 Boulevard Konrad Adenauer, L-2950 Luxembourg (together with its |
|
| December 20, 2024 |
Side Letter, dated December 19, 2024, by and between the Borrower and EIB. Exhibit 10.3 SIDE LETTER RELATING TO AN UP TO EUR 20,000,000 ACCORDION TRANCHE between and Dated: IO BIOTECH APS as Borrower EUROPEAN INVESTMENT BANK as Bank 19 DECEMBER 2024 SIDE LETTER TO FINANCE CONTRACT This side letter (the “Letter”) is made on the date first stated above between: 1) IO BIOTECH APS, company registration no. (CVR) 36474483, C/O COBIS, Ole Maaløes Vej 3, 2200 København N, Denma |
|
| December 20, 2024 |
Exhibit 10.1 Contract number (FI No): 97869 Serapis No: 2024-0179 EIB Internal Classification Level – Corporate Use IO BIOTECH (IEU LS) Finance Contract between the European Investment Bank and IO Biotech ApS Luxembourg and Copenhagen 19 December 2024 WHEREAS: 6 ARTICLE 1 7 1.1 INTERPRETATION 7 1.2 CALCULATIONS OF BASKETS, ETC. 8 1.3 DEFINITIONS 8 ARTICLE 2 18 2.1 AMOUNT OF CREDIT 18 2.2 DISBURSEM |
|
| December 20, 2024 |
Exhibit 99.1 IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025 - Commitment is part of the European Investment Bank’s strategy to support biotech companies with cutting-edge expertise in therapeutic ar |
|
| December 20, 2024 |
Guarantee Agreement, dated December 19, 2024, by and between the Company and EIB. Exhibit 10.2 Contract number (FI No): 97869 Serapis No: 2024-0179 GUARANTEE AGREEMENT IO BIOTECH (IEU LS) By IO Biotech, Inc. as Guarantor in favour of The European Investment Bank TABLE OF CONTENTS 1 DEFINITIONS AND INTERPRETATION 3 2 FIRST DEMAND GUARANTEE 6 3 AUTONOMY OF THE FIRST DEMAND GUARANTEE 7 4 REINSTATEMENT 8 5 SUBORDINATION AND DEFERRAL OF GUARANTOR’S RIGHTS 8 6 DURATION 9 7 REPRESENTA |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 20, 2024 |
Warrant Issuance Agreement, dated December 19, 2024, by and between the Company and EIB. Exhibit 10.4 Contract Number (FI No.)°97869 Serapis No.°2024-0179 EIB Internal Classification Level – Corporate Use DATED DECEMBER 19, 2024 IO BIOTECH (IEU LS) IO BIOTECH, INC. as the Company AND THE EUROPEAN INVESTMENT BANK as the Original Warrantholder WARRANT ISSUANCE AGREEMENT Contents 1. DEFINITIONS AND INTERPRETATION 3 2. THE WARRANTS 18 3. ISSUANCE OF THE WARRANTS 19 4. ANTI-DILUTION PROTEC |
|
| December 16, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF IO BIOTECH, INC. (hereinafter called the “Corporation”) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1. Place of Meetings. Meetings of the stockholders of the Corporation for the election of directors or for any other purpose shall be held at such time and place, if any, either within or without the State of Delaware, as shall be designated from time to t |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2024 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| November 13, 2024 |
IOBT / IO Biotech, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 iobt13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IO Biotech, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 449778109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| November 12, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2024 |
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights Exhibit 99.1 IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights • Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reac |
|
| September 17, 2024 |
IOBT / IO Biotech, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A 1 d794263dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 + |
|
| August 30, 2024 |
Exhibit 99.1 IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications - No new safety signals observed at inter |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2024 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 13, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2024 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| August 13, 2024 |
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights Exhibit 99.1 IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights • Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced |
|
| August 9, 2024 |
IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark August 9, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Vanessa Robertson, Kevin Vaughn Re: IO Biotech, Inc. Form 10-K for the fiscal year ended December 31, 2023 Filed March 5, 2024 File No. 001-41008 Dear Ms. Robertson and Mr. |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| May 14, 2024 |
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights Exhibit 99.1 IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights • Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary end |
|
| May 14, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2024 |
IOBT / IO Biotech, Inc. / Novo Holdings A/S - SC 13G/A Passive Investment SC 13G/A 1 d831751dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 + |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2024 IO BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 24, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Nu |
|
| March 11, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024 As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. |
|
| March 11, 2024 |
IO Biotech, Inc. 2023 Inducement Award Plan. Exhibit 4.4 IO BIOTECH, INC. 2023 INDUCEMENT AWARD PLAN 1. PURPOSE OF PLAN The purpose of this IO Biotech, Inc. 2023 Inducement Award Plan (this “Plan”) of IO Biotech, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company and its Subsidiaries as employees by affording such i |
|
| March 11, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) IO BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity(3) Common Stock, par value $0.001 per |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2024 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41008 IO BIOTECH, INC |
|
| March 5, 2024 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary describes the capital stock of IO Biotech, Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the investors’ rights agreement to which we and certain stockholders are parties (the “IRA”) and of the General Corporation Law |
|
| March 5, 2024 |
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results Exhibit 99.1 IO Biotech Announces 2023 Fourth-Quarter and Year-End Results • Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committ |
|
| March 5, 2024 |
Policy on Recoupment of Incentive Compensation, dated September 20, 2023, of IO Biotech Inc. Exhibit 97.1 IO BIOTECH, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of IO Biotech, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a re |
|
| March 5, 2024 |
Letter Agreement, dated as of October 15, 2022, by and between IO Bio US, Inc. and Amy Sullivan. Exhibit 10.19 3 October 2022 Ms. Amy Sullivan [***] [***] Re: Offer of Employment Dear Amy: I am pleased to offer you full-time employment with IO Bio US, Inc. (the “Company”), a subsidiary IO Biotech ApS (“IO Biotech”), beginning on October 15, 2022 (the “Commencement Date”). As of the Commencement Date you will be employed in the position of Chief Financial Officer, and report to the Chief Execu |
|
| February 14, 2024 |
IOBT / IO Biotech, Inc. / Avoro Capital Advisors LLC - IO BIOTECH, INC. Passive Investment SC 13G/A 1 p24-0287sc13ga.htm IO BIOTECH, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the approp |
|
| February 13, 2024 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Szabina Biro, Hannah Chae, Andres Ortiz Custodio, Kamil Dziedzic, Krishnan Harihanran, Kelvin Kwok, Frank Lui, James Todd, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting |
|
| February 13, 2024 |
IOBT / IO Biotech, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* IO Biotech, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 13, 2024 |
IOBT / IO Biotech, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A 1 d668054dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 + |
|
| February 13, 2024 |
IOBT / IO Biotech, Inc. / HBM Healthcare Investments (Cayman) Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 13, 2024 |
IOBT / IO Biotech, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 iobt13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IO Biotech, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 8, 2024 |
Break Boundaries. Ignite Change. Nasdaq: IOBT Corporate Presentation January 2024 Exhibit 99.1 DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business plan, |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 18, 2023 |
IOBT / IO Biotech, Inc. / Samsara BioCapital, L.P. - SC 13G Passive Investment SC 13G 1 tm2333024d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 449778 10 9 (CUSIP Number) August 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 13, 2023 |
IO Biotech Appoints Helen Collins, MD, to its Board of Directors Exhibit 99.2 IO Biotech Appoints Helen Collins, MD, to its Board of Directors NEW YORK, November 13, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran wi |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| November 13, 2023 |
IO Biotech Announces 2023 Third Quarter Results Exhibit 99.1 IO Biotech Announces 2023 Third Quarter Results • Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma • Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the IASLC 2023 World Conference on Lung Cancer (WCLC) in Sep |
|
| November 13, 2023 |
Severance agreement between the Registrant and Eva Ehrnrooth, dated August 10, 2023 Exhibit 10.3 Severance Agreement This severance agreement (the "Severance Agreement") is entered into 10.8.2023 between: IO Biotech ApS c/o COBIS Ole Maaløes Vej 3 2200 Copenhagen CVR-nr.36474483 (the “Company") and Eva Ehrnrooth (the "Employee") (together the “Parties”) 1. Termination of employment 1.1. Following the negotiations on changes to the Employee’s role in the Company, the Company and t |
|
| September 12, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(2) Registration Number 333-274267 PROSPECTUS Up to 74,131,294 Shares of Common Stock Offered by the Selling Stockholders IO BIOTECH, INC. |
|
| September 7, 2023 |
IOBT / IO Biotech Inc / Kurma Partners - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 449778109 (CUSIP Number) August 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| September 6, 2023 |
IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark September 6, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Cindy Polynice Re: IO Biotech, Inc. Registration Statement on Form S-3, as amended File No. 333-274267 Acceleration Request Requested Date: September 8, 2023 Requested Time: 4:00 |
|
| August 30, 2023 |
As filed with the Securities and Exchange Commission on August 30, 2023. Form S-3 Table of Contents As filed with the Securities and Exchange Commission on August 30, 2023. |
|
| August 30, 2023 |
EX-24.1 Exhibit 24.1 POWER OF ATTORNEY We, the undersigned directors and officers of IO Biotech, Inc. (the Company), hereby severally constitute and appoint Mai-Britt Zocca and Amy Sullivan, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on For |
|
| August 30, 2023 |
Calculation of Filing Fee Tables Form S-3 (Form Type) IO Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry F |
|
| August 16, 2023 |
IOBT / IO Biotech Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 449778109 (CUSIP Number) August 7, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| August 15, 2023 |
IOBT / IO Biotech Inc / HBM Healthcare Investments (Cayman) Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) August 9, 2023** (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| August 14, 2023 |
IOBT / IO Biotech Inc / HBM Healthcare Investments (Cayman) Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) August 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| August 14, 2023 |
IOBT / IO Biotech Inc / Lundbeckfond Invest A/S - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Christian Elling Lundbeckfond Invest A/S Scherfigsvej 7 DK-2100 Copenhagen Ø +45 2062 1276 (Name, Address and Telephone Num |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| August 11, 2023 |
IO Biotech Appoints Heidi Hunter to its Board of Directors EX-99.2 Exhibit 99.2 IO Biotech Appoints Heidi Hunter to its Board of Directors NEW YORK, August 11, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter, an accomplished global biotech |
|
| August 11, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IO BIOTECH, INC., a Delaware corporation IO Biotech, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: A. The name of the Corporation is IO Biotech, Inc. The Corporation’s original certificate of incorporation was filed with the office of the Secretary |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 11, 2023 |
IO Biotech Announces 2023 Second Quarter Results EX-99.1 Exhibit 99.1 IO Biotech Announces 2023 Second Quarter Results • Achieved significant enrollment milestone in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in advanced melanoma; full enrollment anticipated by the end of 2023 • Initiated enrollment in three investigator-initiated trials which the company is supporting to evaluate IO102-IO103 in combination regimens across a variety of |
|
| August 11, 2023 |
IOBT / IO Biotech Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayn |
|
| August 7, 2023 |
IO Biotech, Inc. Announces $75 Million Private Placement Financing Exhibit 99.1 IO Biotech, Inc. Announces $75 Million Private Placement Financing • Offering includes participation from both new and existing healthcare-dedicated investors. • Proceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, August 7, 2023 (GLOBE NEWSWIRE) – IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating c |
|
| August 7, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 7, 2023, is entered into by and among IO BIOTECH, INC., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms us |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 7, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG IO BIOTECH, INC., AND THE PURCHASERS AS SET FORTH HEREIN AUGUST 7, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Securities 5 2.1 Purchase and Sale 5 2.2 Closing 6 3. Representations and Warranties of the Company 6 3.1 Organization and Power 6 3.2 Capitalization 7 3.3 Registration Rights 7 3.4 Authorization 7 3.5 Val |
|
| August 7, 2023 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| August 7, 2023 |
Exhibit 99.2 Cancer Vaccines: The Next Immunotherapy Frontier IO Biotech Breaking boundaries. Igniting change. Nasdaq: IOBT Corporate Overview Summer 2023 © 2023 IO Biotech, Inc. Confidential O Co v n efr id vie en w tial Overview 1 Disclaimer and Forward-Looking Statements This presentation is provided solely for informational purposes and has been prepared to assist interested parties in making |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 18, 2023 |
EX-99.1 Exhibit 99.1 IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer • Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines bas |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 14, 2023 |
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone EX-99.1 Exhibit 99.1 IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone • 225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced melanoma; trial protocol calls for an interim analysis of overall response rate (ORR) one year after 225 patients have been randomized • Data obt |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 11, 2023 |
IO Biotech Announces 2023 First-Quarter Results EX-99.1 Exhibit 99.1 IO Biotech Announces 2023 First-Quarter Results • The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma by mid-2023 and to fully enroll the trial by the end of 2023. • The Phase 3 trial protocol calls for an interim analysis of overall response rate (ORR) one year after 225 patients have been randomized; data obtained fro |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| April 26, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 26, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2023 IO BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 14, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| March 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41008 IO BIOTECH, INC |
|
| March 14, 2023 |
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results EX-99.1 Exhibit 99.1 IO Biotech Announces 2022 Fourth-Quarter and Year-End Results • Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023. • The Phase 3 trial protocol calls for an interim analysis of overall response rat |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 14, 2023 |
Letter Agreement, dated as of October 15, 2022, by and between IO Bio US, Inc. and Amy Sullivan. Exhibit 10.19 3 October 2022 Ms. Amy Sullivan [***] [***] Re: Offer of Employment Dear Amy: I am pleased to offer you full-time employment with IO Bio US, Inc. (the “Company”), a subsidiary IO Biotech ApS (“IO Biotech”), beginning on October 15, 2022 (the “Commencement Date”). As of the Commencement Date you will be employed in the position of Chief Financial Officer, and report to the Chief Execu |
|
| March 14, 2023 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary describes the capital stock of IO Biotech, Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the investors’ rights agreement to which we and certain stockholders are parties (the “IRA”) and of the General Corporation Law |
|
| March 14, 2023 |
EX-99.1 OUR GOAL: Establish our T-win® immune-modulating cancer vaccines as the potential backbone of therapy for multiple cancer types Nasdaq: IOBT Corporate Overview March 2023 Exhibit 99.1 Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 15, 2023 |
EX-1.1 2 d264518dex11.htm EX-1.1 Exhibit 1.1 IO BIOTECH, INC. $75,000,000 COMMON STOCK SALES AGREEMENT February 15, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: IO Biotech, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time |
|
| February 15, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| February 15, 2023 |
Up to $19,500,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-269569 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 10, 2023) Up to $19,500,000 Common Stock We have entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, whom we refer to as the agent, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement |
|
| February 14, 2023 |
IOBT / IO Biotech Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
IOBT / IO Biotech Inc / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* IO BIOTECH, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2023 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 boa-poa2.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Kelvin Kwok, Tolu Tade, Andres Ortiz Custodio, Frank Lui, James Todd, Zainab Tarteel, Hannah Chae and Monica Yako as an attorney-in-fact for the Corporation acting for the Corporation and in the Corpora |
|
| February 14, 2023 |
IOBT / IO Biotech Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d7sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* IO Biotech, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) December 31, |
|
| February 9, 2023 |
IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N IO Biotech, Inc. Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark February 9, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tyler Howes Re: IO Biotech, Inc. Registration Statement on Form S-3, as amended File No. 333-269569 Acceleration Request Requested Date: February 10, 2023 Requested Time: 4:00 P.M |
|
| February 6, 2023 |
EX-4.3 Exhibit 4.3 IO BIOTECH, INC. 2021 EQUITY AND INCENTIVE PLAN I. INTRODUCTION 1.1 Purposes. The purposes of the IO Biotech, Inc. 2021 Equity and Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to advance the |
|
| February 6, 2023 |
As filed with the Securities and Exchange Commission on February 6, 2023 S-8 As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. |
|
| February 6, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) IO BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity(3) Common Stock, par value $0.001 per |
|
| February 3, 2023 |
Calculation of Registration Fee Table. EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) IO Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist |
|
| February 3, 2023 |
EX-4.1 Exhibit 4.1 IO BIOTECH, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 3 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series. 4 Section 2.2. Est |
|
| February 3, 2023 |
As filed with the Securities and Exchange Commission on February 3, 2023. S-3 Table of Contents As filed with the Securities and Exchange Commission on February 3, 2023. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 9, 2023 |
IO Biotech Provides Business Update EX-99.2 3 d448682dex992.htm EX-99.2 Exhibit 99.2 IO Biotech Provides Business Update • Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling patients at more than 80 active sites globally. • Encouraging initial data |
|
| January 9, 2023 |
EX-99.1 2 d448682dex991.htm EX-99.1 OUR GOAL: Establish our T-win® immune-modulating cancer vaccines as the backbone of therapy for multiple cancer types Nasdaq: IOBT Corporate Overview January 2023 Exhibit 99.1 Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as ame |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| November 9, 2022 |
IO Biotech Announces Third Quarter Results for 2022 EX-99.1 Exhibit 99.1 IO Biotech Announces Third Quarter Results for 2022 • Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company’s global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma • Oral presentation and two poster presentations at the Society for I |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 13, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| October 13, 2022 |
IO Biotech Announces Appointment of New Chief Financial Officer Exhibit 99.1 IO Biotech Announces Appointment of New Chief Financial Officer New York, New York ? October 13, 2022: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win? technology platform, today announced the appointment of Amy Sullivan as the company?s new Chief Financial Officer. ?We are pleased to welcome |
|
| September 30, 2022 |
IOBT / IO Biotech Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayn |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| August 11, 2022 |
IO Biotech Announces Second Quarter Results for 2022 Exhibit 99.1 IO Biotech Announces Second Quarter Results for 2022 ? Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103 and KEYTRUDA? (pembrolizumab) as first-line treatment in advanced melanoma ? Announced initiation and dosing of first patient in Phase 2 Trial of IO102-IO103 in combination with KEYTRUDA? (pembrolizumab) as first line treatment in m |
|
| May 26, 2022 |
IOBT / IO Biotech Inc / Novo Holdings A/S - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kenned |
|
| May 26, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 IO Biotech, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 16, 2022 |
Exhibit 99.1 IO Biotech Announces First Quarter Results for 2022 ? Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April? ?Announced initiation and dosing of first patient in Phase 2 Trial of IOB102-IOB103 in combination with KEYTRUDA? (pembrolizumab) as first line treatment in multi-arm basket t |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 25, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of IO Biotech, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersig |
|
| April 25, 2022 |
IOBT / IO Biotech Inc / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) April 13, 2022 (Date of Event Which Requires Filing o |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ?240. |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2022 IO BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 31, 2022 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following summary describes the capital stock of IO Biotech, Inc. (the ?Company,? ?we,? ?us,? and ?our?) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the investors? rights agreement to which we and certain stockholders are parties (the ?IRA?) and of the General Corporation Law |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 31, 2022 |
Exhibit 99.1 IO Biotech Announces Year-End Results for 2021 ?Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma to be Presented at AACR in April? ? Began Patient Recruitment for Global Phase 3 Combination Trial with Lead Asset IO102-IO103 and KEYTRUDA? (pembrolizumab) as First-Line Treatment in Advanced Melanoma? ?Stron |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41008 IO BIOTECH, INC |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 3, 2022 |
IO Biotech Announces Appointment of David V. Smith to its Board of Directors Exhibit 99.1 IO Biotech Announces Appointment of David V. Smith to its Board of Directors New York, New York ? March 3, 2022: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win? technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors. Mr. Smith, a veteran biotech execu |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2022 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| February 11, 2022 |
IOBT / IO Biotech Inc / HBM Healthcare Investments (Cayman) Ltd. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 11, 2022 |
IOBT / IO Biotech Inc / Avoro Capital Advisors LLC - IO BIOTECH, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 8, 2022 |
As filed with the Securities and Exchange Commission on February 8, 2022 As filed with the Securities and Exchange Commission on February 8, 2022 Registration No. |
|
| February 8, 2022 |
FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) IO BIOTECH, INC. |
|
| December 17, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF IO BIOTECH, INC. (hereinafter called the ?Corporation?) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1. Place of Meetings. Meetings of the stockholders of the Corporation for the election of directors or for any other purpose shall be held at such time and place, if any, either within or without the State of Delaware, as shall be designated from time to t |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41008 IO Biotech, Inc. |
|
| December 17, 2021 |
Exhibit 99.1 IO BIOTECH APS Balance Sheets (In thousands, except share and per share amounts) (unaudited) June 30, 2021 December 31, 2020 Restated Assets Current assets Cash and cash equivalents $ 54,752 $ 3,405 Prepaid expenses and other current assets 5,410 2,230 Total current assets 60,162 5,635 Noncurrent assets 38 18 Total assets $ 60,200 $ 5,653 Liabilities, convertible preference shares and |
|
| December 17, 2021 |
Amended and Restated Certificate of Incorporation of IO Biotech, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IO BIOTECH, INC., a Delaware corporation IO Biotech, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: A. The name of the Corporation is IO Biotech, Inc. The Corporation?s original certificate of incorporation was filed with the office of the Secretary |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2021 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| December 6, 2021 |
Exhibit 10.1 EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Clinical Trial Collaboration and Supply Agreement by and among MSD International GmbH, MSD International Business GmbH, and Collaborator (as defined below) Clinical Trial Colla |
|
| December 6, 2021 |
Exhibit 99.1 IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA? (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types New York, New York ? December 6, 2021: IO Biotech (Nasdaq: IOBT), a clinical-sta |
|
| December 6, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2021 IO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-41008 87-0909276 (State or other jurisdiction of incorporation) (Commission File |
|
| November 19, 2021 |
IOBT / IO Biotech Inc / Lundbeckfond Invest A/S - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Christian Elling Lundbeckfond Invest A/S Scherfigsvej 7 DK-2100 Copenhagen Ø +45 2062 1276 (Name, Address and Telephone Numb |
|
| November 19, 2021 |
IOBT / IO Biotech Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) November 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 19, 2021 |
EXHIBIT 99.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Keith Vendola, Mai-Britt Zocca, and Brian Burkavage, or any of them acting individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit t |
|
| November 12, 2021 |
IOBT / IO Biotech Inc / Vivo Capital IX, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common stock, par value $ 0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) November 9, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 10, 2021 |
IOBT / IO Biotech Inc / Novo Holdings A/S - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* IO Biotech, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 449778109 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne K |
|
| November 10, 2021 |
Exhibit 99.1 EXECUTION VERSION LOCK-UP AGREEMENT June 14th, 2021 Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC As representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: T |
|
| November 8, 2021 |
424B4 1 d180178d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Number 333-260301 and 333-260796 7,150,000 Shares COMMON STOCK IO Biotech, Inc. is offering 7,150,000 shares of common stock. This is our initial public offering and no public market currently exists for our common stock. The initial public offering price is $14.00 per share. We have been approved to li |
|
| November 5, 2021 |
IO Biotech, Inc. Update to Preliminary Prospectus Issued November 1, 2021 FWP 1 d180178dfwp.htm FWP Free Writing Prospectus Filed Pursuant to Rule 433 under the Securities Act of 1933 Issuer Free Writing Prospectus dated November 4, 2021 Relating to Preliminary Prospectus dated November 1, 2021 Registration Statement No. 333-260301 IO Biotech, Inc. Update to Preliminary Prospectus Issued November 1, 2021 This free writing prospectus relates to the initial public offerin |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 S-1MEF 1 d180178ds1mef.htm S-1MEF As filed with the Securities and Exchange Commission on November 4, 2021 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IO BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 2834 84-0909276 (State or other jurisdiction of in |
|
| November 2, 2021 |
November 2, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Celeste Murphy Daniel Crawford David Burton Al Pavot Re: IO Biotech, Inc. Registration Statement on Form S-1 File No. 333-260301 Acceleration Request Requested Date: November 4, 2021 Requested Time: 3:00 p.m., Eastern Standard Time Ladies and Gentlemen: In a |
|
| November 2, 2021 |
November 2, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Celeste Murphy Daniel Crawford David Burton Al Pavot Re: IO Biotech, Inc. Registration Statement on Form S-1 File No. 333-260301 Acceleration Request Requested Date: November 4, 2021 Requested Time: 3:00 P.M., Eastern Time Ladies and Gentlemen |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 IO Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware 87-0909276 (State of incorporation or organization) (I.R.S. Employer Identification No.) Ole Maal?es Vej 3 DK-2200 C |
|
| November 1, 2021 |
Exhibit 10.2 IO BIOTECH, INC. 2021 EQUITY AND INCENTIVE PLAN I. INTRODUCTION 1.1 Purposes. The purposes of the IO Biotech, Inc. 2021 Equity and Incentive Plan (this ?Plan?) are (i) to align the interests of the Company?s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company?s growth and success, (ii) to advance the intere |
|
| November 1, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IO BIOTECH, INC., a Delaware corporation IO Biotech, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: A. The name of the Corporation is IO Biotech, Inc. The Corporation?s original certificate of incorporation was filed with the office of the Secretary |
|
| November 1, 2021 |
As filed with the Securities and Exchange Commission on November 1, 2021. Table of Contents As filed with the Securities and Exchange Commission on November 1, 2021. |
|
| November 1, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF IO BIOTECH, INC. (hereinafter called the ?Corporation?) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1. Place of Meetings. Meetings of the stockholders of the Corporation for the election of directors or for any other purpose shall be held at such time and place, if any, either within or without the State of Delaware, as shall be designated from time to t |
|
| November 1, 2021 |
Form of Indemnification Agreement Exhibit 10.1 DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this ?Agreement?) is entered into as of the [?] day of [?], 2021, by and between IO Biotech, Inc., a Delaware corporation (the ?Company?), and [?] (?Indemnitee?). RECITALS A. The Company is aware that competent and experienced persons are increasingly reluctant to serve or continue serving as directors or o |
|
| November 1, 2021 |
Form of Underwriting Agreement Exhibit 1.1 [?] Shares IO Biotech, Inc. COMMON STOCK (PAR VALUE [?]) UNDERWRITING AGREEMENT [?], 2021 [?], 2021 Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC As representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue N |
|
| November 1, 2021 |
Exhibit 10.3 IO BIOTECH, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the IO Biotech, Inc. 2021 Employee Stock Purchase Plan (this ?Plan?) is to provide eligible Employees of the Company and Participating Subsidiaries with a convenient means of acquiring an equity interest in the Company through payroll deductions or other contributions in order to enhance such employees? sens |
|
| November 1, 2021 |
Exhibit 4.1 . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.001 Certificate Shares Number * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * ZQ00000000 * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * IO BIOTECH, INC. * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * INCORPORATED UNDER THE LAWS O |
|
| November 1, 2021 |
Exhibit 10.13 INVESTORS? RIGHTS AGREEMENT THIS INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of October 29, 2021, by and among IO Biotech, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?, and each of the stockholders listed on Schedule B hereto, each of whom is referred |
|
| October 26, 2021 |
Service Agreement, dated August 21, 2017, by and between IO Biotech ApS and Eva Ehrnrooth Exhibit 10.16 Service Agreement This service agreement is entered into between: IO Biotech ApS [***] (the ?Company?) and Eva Ehrnrooth (the ?CMO?) 1 Commencement of employment and title 1.1 With effect from 1 October 2017, the CMO will be employed as Chief Medical Officer (CMO) in the Company on the terms and conditions set forth in this service agreement (the ?Agreement?). 1.2 The CMO reports to |
|
| October 26, 2021 |
Exhibit 10.10 2nd AMENDMENT TO OPTION ASSIGNMENT AGREEMENT BETWEEN HERLEV AND GENTOFTE HOSPITAL AND IO BIOTECH ApS (Assignment of Arginase 1) On 7 December 2018, the following parties Herlev and Gentofte Hospital [***] (hereinafter referred to as the ?Hospital?) and IO Biotech ApS [***] (hereinafter referred to as the ?Company?) (hereinafter collectively referred to as the ?Parties? and individual |
|
| October 26, 2021 |
Exhibit 10.8 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. OPTION ASSIGNMENT AGREEMENT BETWEEN HERLEV AND GENTOFTE HOSPITAL AND IO BIOTECH ApS (Option on assignment of Arginase 1) On 27 March, 2017, the following parties Herlev and Gentofte Hospital [***] (hereinafter referred to as ?Hospital?) and IO |
|
| October 26, 2021 |
Exhibit 21.1 Subsidiaries of the Registrant Legal Name of Subsidiary Jurisdiction of Organization IO Biotech ApS Denmark IO Bio US, Inc. Delaware, United States IO Biotech Limited England and Wales |
|
| October 26, 2021 |
Exhibit 10.11 Execution version Agreement on Payment for Specific Services IO Biotech ApS and Herlev og Gentofte Hospital This agreement (the ”Agreement”) is made on 27 January 2021 between IO Biotech ApS [***] (the “Company”) and Herlev og Gentofte Hospital [***] (the “Hospital”) (the Company and the Hospital hereinafter collectively referred to as the “Parties” and each as a “Party”) WHEREAS A. |
|
| October 26, 2021 |
Exhibit 10.12 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and among MSD International GmbH, MSD International Business GmbH, and IO Biotech ApS TABLE OF CONTENTS Page 1. Definitions 1 2. Scope of the Agreement 9 2.1 Generally 9 2.2 Manufacturing D |
|
| October 26, 2021 |
Exhibit 10.9 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. 1st AMENDMENT TO OPTION ASSIGNMENT AGREEMENT BETWEEN HERLEV AND GENTOFTE HOSPITAL AND IO BIOTECH ApS (1st amendment to Option Assignment Agreement of Arginase 1) On December 7th 2018, the following parties Herlev and Gentofte Hospital [***] (h |
|
| October 26, 2021 |
Addendum to Service Agreement, dated April 1, 2021, by and between IO Biotech ApS and Eva Ehrnrooth Exhibit 10.17 Addendum to Service Agreement This addendum to the service agreement dated 21 August 2017 (the ?Addendum?) is entered into between: IO Biotech ApS [***] (the ?Company?) and Eva Ehrnrooth (the ?CMO?) 1 Remuneration 1.1 Effective from 1 April 2021, the monthly gross salary is DKK 187,500 payable monthly in arrears on the last working day of each month at the latest. 2 Pension scheme 2. |
|
| October 26, 2021 |
Exhibit 10.15 Addendum to Service Agreement This addendum to the service agreement dated 21 August 2017 (the ?Addendum?) is entered into between: IO Biotech ApS [***] (the ?Company?) and Mai-Britt Zocca (the?CEO?) 1 Remuneration 1.1 Effective from 1 April 2021, the annual gross salary amounts to DKK 2,400,000. The salary is pay 1/12 monthly in arrears not later than on the last business day of eac |
|
| October 26, 2021 |
Service Agreement, dated August 21, 2017, by and between IO Biotech ApS and Mai-Britt Zocca Exhibit 10.14 Execution version Service Agreement IO Biotech ApS ? Mai-Britt Zocca This service agreement is entered into between: IO Biotech ApS [***] (the ?Company?) and Mai-Britt Zocca (the ?CEO?) 1 Date of employment 1.1 With effect from 1 January 2018 the CEO is employed as Chief Executive Officer of the Company on the terms and conditions set forth in this Service Agreement. The CEO has been |
|
| October 26, 2021 |
Exhibit 10.6 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. FRAMEWORK ASSIGNMENT AGREEMENT BETWEEN HERLEV HOSPITAL AND IO BIOTECH ApS On 2016, the following parties Herlev Hospital [***] (hereinafter referred to as ?Hospital?) and IO Biotech ApS [***] (hereinafter referred to as the ?Company?) have ent |
|
| October 26, 2021 |
Exhibit 10.7 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. ASSIGNMENT AGREEMENT BETWEEN HERLEV AND GENTOFTE HOSPITAL AND IO BIOTECH ApS On 2016, the following parties Herlev and Gentofte Hospital [***] (hereinafter referred to as “Hospital”) and IO Biotech ApS [***] (hereinafter referred to as the “Co |
|
| October 26, 2021 |
As filed with the Securities and Exchange Commission on October 26, 2021. As filed with the Securities and Exchange Commission on October 26, 2021. Registration No. 333-260301 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IO Biotech, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization |
|
| October 26, 2021 |
Exhibit 10.4 *Portions of this exhibit have been excluded because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. OPTION ASSIGNMENT AGREEMENT between IO Biotech ApS and Herlev Hospital Option Assignment Agreement THIS OPTION ASSIGNMENT AGREEMENT (this ?Agreement?) shall come into force and be effective as of the Effective Date as defined below, cf. Clause |
|
| October 26, 2021 |
Exhibit 10.5 ADDENDUM I TO OPTION ASSIGNMENT AGREEMENT between IO Biotech ApS and Herlev Hospital Addendum to Option Assignment Agreement THIS ADDENDUM (hereinafter referred to as the ?Addendum?) is entered into on the date last mentioned below by and between IO Biotech ApS [***] (hereinafter referred to as the ?Company?) and Herlev Hospital (Region Hovedstaden) [***] (hereinafter referred to as t |
|
| October 15, 2021 |
Power of Attorney (included on the signature page to this Registration Statement) Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021. |
|
| October 6, 2021 |
DRS/A 1 filename1.htm Table of Contents Confidential draft submitted to the Securities and Exchange Commission on October 5, 2021. This draft registration statement has not been filed with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATI |
|
| October 5, 2021 |
SIDLEY AUSTIN LLP 787 SEVENTH AVENUE NEW YORK, NY 10019 +1 212 839 5300 +1 212 839 5599 FAX AMERICA ? ASIA PACIFIC ? EUROPE October 5, 2021 U. |
|
| August 9, 2021 |
Table of Contents Confidential draft submitted to the Securities and Exchange Commission on August 9, 2021. |
|
| August 9, 2021 |
SIDLEY AUSTIN LLP 787 SEVENTH AVENUE NEW YORK, NY 10019 +1 212 839 5300 +1 212 839 5599 FAX AMERICA ? ASIA PACIFIC ? EUROPE August 9, 2021 U. |
|
| June 3, 2021 |
Confidential draft submitted to the Securities and Exchange Commission on June 2, 2021. |
